However, TIDE failed to predict response to immunotherapy in HCC (P = .7), as shown in Figure 5D. We then evaluated whether the potential HCC groups were significantly changed in response to CTLA4 and PD1 inhibitor treatment, and the results showed that the high-risk group was likely to respond to PD1 inhibitor treatment, as shown in Figure 5E, which was consistent with the results in Figure 5C. Here, CTLA4 is linked to hepatocellular carcinoma.